Stroke in type 2 diabetes

British Journal of Diabetes and Vascular Disease

Volumn 8, Issue 5, 2008, Pages 222-229

  Sander, Dirk ^a,b   Sander, Kerstin ^a,b   Poppert, Holger ^b  

^a Medical Park Hospital   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Diabetes mellitus; Epidemiology; Risk factors; Sex differences; Stroke; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; METFORMIN; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RAMIPRIL; SULFONYLUREA; TELMISARTAN; WARFARIN;

AGE DISTRIBUTION; BRAIN ATHEROSCLEROSIS; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; PROTEINURIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SMOKING; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

EID: 58049125753     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/1474651408096677     Document Type: Review

References (89)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997: 349:1269-76.
2. Sacco RL, Benjamin EJ, Broderick JP et al. American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. Stroke 1997; 28:1507-17.
3. Bell DS. Stroke in the diabetic patient. Diabetes Care 1994; 17:213-19.
4. Kissela BM, khoury J, Kleindorfer D et al. Epidemiology of ischemic stroke in patients with diabetes: the greater Cincinnati/ Northern Kentucky Stroke Study. Diabetes Care 2005; 28:355-9.
5. Folsom AR, Rasmussen ML, Chambles LE et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigations. Diabetes Care 1999;22:1077-83.
6. Mankovsky BN, Metzger BE, Molitch ME, Biller J. Cerebrosvascular disorders in patients with diabetes mellitus. J. Diabetes Complications 1996; 10:228-42.
7. Jorgensen H, Nakayama H, Raaschou HO, Olsen TS. Stroke in patients with diabetes. The Copenhagen Stroke Study. Stroke 1994; 25:1977-84.
8. Boden-Abala B, Sacco RL, Lee HS et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke 2008; 39:30-5.
9. Arauz A, Murillo L, Cantu C, Barinagarrementeria F, Higuera J. Prospective study of single and multiple lacunar infarcts using magnetic resonance imaging: risk factors, recurrance, and outcome in 175 consecutives cases. Stroke 2003; 34:2453-8.
10. Eguchi K, Kario K, Shimada K. Greater impact of coexistence of hypertension tension and diabetes on silent cebral infarcts. Stoke 2003; 34:2471-4.
11. Tuttolomondo A, Pinto A, Salemi G et al. Diabetic and non-diabetic subjects with ischemic stroke: differences, subtype distribution and outcome. Nutr Metab Cardiovasc Dis 2008; 18:152-71
12. Hankey GJ, Jamrozik K, Broadhurst RJ et al. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stoke 1998; 29:2491-500.
13. Nannetti L, Paci M, Baccini M, Rinaldi LA, Taiti PG. Recovery from stroke in patients with diabetes mellitus. J Diabetes Complications 2008 Apr 14 [Epub ahead of print].
14. Megherbi SE, Milan C, Minier D et al. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project. Stroke 2003; 34:688-94.
15. Tuomilehto J, Rastenyte D, Jousilahti P, Sarti C, Vartiainen E. Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. Stroke 1996; 27:210-15.
16. Sprafka JM, Virnig BA, Shahar E, McGovern PG. Trends in diabetes prevalence among stroke patients and the effect of diabetes on stroke survival: the Minnesota Heart Survey. Diabet Med 1994; 11:678-84.
17. Olsson T, Viitanen M, Asplund K, Eriksson S, Hagg E. Prognosis after stroke in diabetic patients. A controlled prospective study. Diabetologia 1990; 33:244-9.
18. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154:635-41.
19. Mulnier HE, Seaman HE, Raleigh VS et al. Risk of stroke in people with type 2 diabetes in the UK: a study using the General Practice Research Database. Diabetologia 2006; 49:2859-65.
20. Hu G, Sarti C, Jousilahti P et al. The impact of history of hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality. Stroke 2005; 36:2538-43.
21. Giorda CB, Avogaro A, Maggini M et al. Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke 2007; 38:1154-60.
22. Kang SS, Littooy FN, Gupta SR et al. Higher prevalence of abdominal aortic aneurysms in patients with carotid stenosis but without diabetes. Surgery 1999; 126:687-91; discussion 691-2.
23. Ahari A, Bergqvist D, Troeng T et al. Diabetes mellitus as a risk factor for early outcome after carotid endarterectomy: a population-based study. Eur J Vasc Endovasc Surg 1999; 18:122-6.
24. Kuhan G, Gardiner ED, Abidia AF et al. Risk modelling study for carotid endarterectomy. Br J Surg 2001; 88:1590-4.
25. Poppert H, Wolf O, Theiss W et al. MRI lesions after invasive therapy of carotid artery stenosis: a risk-modeling analysis. Neurol Res 2006; 28:563-7.
26. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004; 44:2293-300.
27. Yokoyama H, Katakami N, Yamasaki Y. Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Stroke 2006; 37:2420-7.
28. Tiehuis AM, van der Graaf Y, Visseren FL et al. Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease. Stroke 2008; 39:1600-03.
29. Honda M, Kitagawa N, Tsutsumi K et al. High-resolution magnetic resonance imaging for detection of carotid plaques. Neurosurgery 2006; 58:338-46; discussion 338-46.
30. Esposito L, Sievers M, Sander D et al. Detection of unstable carotid artery stenosis using MRI. J Neurol 2007; 254:1714-22.
31. Takaya N, Yuan C, Chu B et al. Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events: a prospective assessment with MRI: initial results. Stroke 2006; 37: 818-23.
32. Lin K, Zhang ZQ, Detrano R, Lu B, Fan ZM. Carotid vulnerable lesions are related to accelerated recurrence for cerebral infarction magnetic resonance imaging study. Acad Radiol 2006; 13:1180-6.
33. Esposito L, Heider P, Wolf O et al. Carotid artery stenosis: diagnosis of diabetes predicts increased vulnerability of plaques irrespective of the degree of stenosis. Cerebrovasc Dis 2008; 25:20.
34. Stevens RJ, Coleman RL, Adler Al et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 2004; 27:201-07.
35. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19:403-18.
36. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
37. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-31.
38. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-07.
39. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-59.
40. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271:840-4.
41. Lakshminarayan K, Anderson DC, Herzog CA, Qureshi Al. Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States. Neurologist 2008; 14:143-50.
42. Smith PJ, Hurlen M, Abdelnoor M, Arnesen H. Less benefit from warfarin in diabetics after myocardial infarction? Cardiology 2008; 111:161-6.
43. Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006; 113:e4O9-e449.
44. Wang TJ, Parise H, Levy D et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292:2471-17.
45. Shelgikar KM, Hockaday TD, Yajnik CS. Central rather than generalized obesity is related to hyperglycaemia in Asian Indian subjects. Diabet Med 1991; 8:712-17.
46. Mozaffarian D, Marfisi R, Levantesi G, et al. Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet 2007; 370:667-75.
47. Tanne D, Koren-Morag N, Goldbourt U. Fasting plasma glucose and risk of incident ischemic stroke or transient ischemic attacks: a prospective cohort study. Stroke 2004; 35:2351-5.
48. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001; 32:2426-32.
49. Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141:421-31.
50. Batty GD, Kivimaki M, Davey Smith G, Marmot MG, Shipley MJ. Post-challenge blood glucose concentration and stroke mortality rates in non-diabetic men in London: 38-year follow-up of the original Whitehall prospective cohort study. Diabetologia 2008; 51:1123-6.
51. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854-65.
52. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352:837-53.
53. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996; 27:63-8.
54. Sacco RL, Benson RT, Kargman DE et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 2001; 285:2729-35.
55. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 2008; 196:489-96.
56. Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med 2003; 163: 669-76.
57. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685-96.
58. Keech A, Colquhoun D, Best J et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003; 26:2713-21.
59. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
60. Amarenco P, Bogousslavsky J, Callahan A 3rd et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549-59.
61. Collaborators CTTC, Kearney PM, Blackwell L et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117-25.
62. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia and the risk of stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Stroke 1998; 29:1860-6.
63. Matsumoto K, Miyake S, Yano M et al. Insulin resistance and classic risk factors in type 2 diabetic patients with different subtypes of ischemic stroke. Diabetes Care 1999; 22:1191-5.
64. Najarian RM, Sullivan LM, Kannel WB, Wilson PW, D'Agostino RB, Wolf PA. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med 2006; 166:106-11.
65. Meerarani P, Badimon JJ, Zias E, Fuster V, Moreno PR. Metabolic syndrome and diabetic atherothrombosis: implications in vascular complications. Curr Mol Med 2006; 6:501-14.
66. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96:1432-7.
67. Henry RM, Kostense PJ, Dekker JM et al. Carotid arterial remodeling: a maladaptive phenomenon in type 2 diabetes but not in impaired glucose metabolism: the Hoorn study. Stroke 2004; 35:671-6.
68. Wagenknecht LE, D'Agostino R Jr, Savage PJ, O'Leary DH, Saad MF, Haffner SM. Duration of diabetes and carotid wall thickness. The Insulin Resistance Atherosclerosis Study (IRAS). Stroke 1997; 28: 999-1005.
69. Howard BV, Roman MJ, Devereux RB et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008; 299:1678-89.
70. Gillett M, Davis WA, Jackson D, Bruce DG, Davis TM. Prospective evaluation of carotid bruit as a predictor of first stroke in type 2 diabetes: the Fremantle Diabetes Study. Stroke 2003; 34:2145-51.
71. Cheung N, Rogers S, Couper DJ, Klein R, Sharrett AR, Wong TY. Is diabetic retinopathy an independent risk factor for ischemic stroke? Stroke 2007; 38:398-401.
72. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998; 29:635-9.
73. Guerrero-Romero F, Rodriguez-Moran M. Proteinuria is an independent risk factor for ischemic stroke in non-insulin-dependent diabetes mellitus. Stroke 1999; 30:1787-91.
74. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke 1997; 28:557-63.
75. You RX, McNeil JJ, O'Malley HM, Davis SM, Thrift AG, Donnan GA. Risk factors for stroke due to cerebral infarction in young adults. Stroke 1997; 28:1913-18.
76. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Stroke recurrence: predictors, severity, and prognosis. The Copenhagen Stroke Study. Neurology 1997; 48:891-5.
77. Idris I, Thomson GA, Sharma JC. Diabetes mellitus and stroke. Int J Clin Pract 2006; 60:48-56.
78. Johnston SC, Rothwell PM, Nguyen-Huynh MN et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 2007; 369:283-92.
79. Fateh-Moghadam S, Plockinger U, Cabeza N et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005; 42:99-103.
80. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DIM, Horwitz RI. Insulin resistance and risk for stroke. Neurology 2002; 59:809-15.
81. Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 2007; 153:445 e1-e6.
82. Kernan WN, Inzucchi SE, Viscoli CM et al. Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. Stroke 2003; 34:1431-6.
83. Takano H, Hasegawa H, Zou Y, Komuro I. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des 2004; 10:2779-86.
84. Nakamura T, Yamamoto E, Kataoka K et al. Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke 2007; 38:3016-22.
85. Kielian T, Drew PD. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J Neurosci Res 2003; 71:315-25.
86. Tureyen K, Kapadia R, Bowen KK et al. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem 2007; 101:41-56.
87. Wilcox R, Bousser MG, Betteridge DJ et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38:865-73.
88. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-89.
89. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298:1180-8.